Cooperative Agreement U88EH001097

This Project Grant award from the National Human Genome Research Institute (CFDA 93.172 - Human Genome Research) will provide $415,712 to Research Triangle Institute (RTI International) to study how public health newborn screening programs should determine which genes to include in sequencing panels. The key objectives are to: Appraise and contrast the approaches and criteria used by experts conducting newborn sequencing studies to determine which genes to screen, synthesizing decision...

The National Institute of Child Health and Human Development (NICHD) awarded a $223,500 Project Grant (CFDA 93.865 - Child Health and Human Development Extramural Research) to the University of Alabama for the project "Optimal Newborn Screening Algorithms - Efficacy and Equity." The goal of this 2-year research project is to develop a framework for designing optimal newborn screening algorithms that are accurate and equitable, using cystic fibrosis as a model disorder. Key objectives...

The North Dakota Department of Health and Human Services (NDDHHS) was awarded a $1,380,000 Maternal and Child Health Federal Consolidated Programs (CFDA 93.110) grant from the Health Resources and Services Administration (HRSA). The 4-year project, which commenced on July 1, 2024, aims to improve health outcomes for newborns and children with heritable conditions identified through North Dakota's newborn screening program. Key objectives include: Enhancing public and provider education on the...

This federal Cooperative Agreement award from the Centers for Disease Control and Prevention (CDC) under the Investigations and Technical Assistance program (CFDA 93.283) provides $2,000,000.00 to the Florida Department of Health (FDOH) to establish a Center of Excellence focused on enhancing disease detection in newborns. The key products and services to be delivered under this 4-year award, which runs from September 30, 2024 to September 29, 2028, include the implementation of innovative...

This $2,442,535 Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865) will fund research to understand the long-term impact and value of implementing newborn genomic sequencing. The key objectives are to: Conduct interviews with clinicians, health system leaders, and newborn screening program coordinators to understand their needs and concerns regarding integrating newborn genomic sequencing with traditional screening programs. Follow up with...

This Project Grant award, funded by the Agency for Healthcare Research and Quality (AHRQ) under the Research on Healthcare Costs, Quality and Outcomes (CFDA 93.226) program, supports a comprehensive $398,972 study on improving healthcare quality and equity for newborns with prenatal substance exposure. The study, conducted by the University of California, Davis in collaboration with the Better Outcomes through Research for Newborns (BORN) network and the EMPOWER stakeholder group, aims to:...

This $295,923 Project Grant award from the National Institute of Environmental Health Sciences (NIEHS) under the Environmental Health (CFDA 93.113) program aims to optimize and validate a low-cost, minimally-invasive dried blood spot (DBS) collection device for accurately quantifying low blood lead levels (BLLs) in a single drop of capillary blood. The device will incorporate innovative and patented technologies to remove lead contamination from the filter paper, protect the paper from...

This federal Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) will provide $148,000 to the University of North Texas Health Science Center at Fort Worth to explore the multilevel determinants of implementation of prenatal syphilis screening policies into clinical practice among obstetric providers. The key objectives are to: 1) Assess the multilevel determinants,...

This $664,837 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) aims to comprehensively screen newborns for in-utero SARS-CoV-2 infection and assess associated immune responses and clinical outcomes. The primary objectives are to: 1) Identify newborns with in-utero SARS-CoV-2 infection using a multi-faceted approach involving antibody and PCR testing of cord blood, placental...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), provides $578,935 to the University of Washington to develop and explore new technology for massively parallel, rapid, and inexpensive biochemical annotation of DNA variants of unknown significance (VOUS). The goal is to address the false negative problem associated with ignoring VOUS in newborn sequencing...